Algorae Pharmaceuticals Limited (ASX: 1AI) - Share Price

Current share price for 1AI : $0.014 0.001 (3.85%)⁺

Algorae Pharmaceuticals Limited is a pharmaceutical development company with three drug candidates and a proprietary artificial intelligence (AI), an ASX-listed company, biopharmaceutical prediction platform under development. The therapeutic pipeline comprises AI-116 for dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson disease.

1AI General Information ⁺

ASX Code	1AI
Website	http://www.algoraepharma.com
Industry/Sector	Biotechnology
Market Cap ($M)	27
1AI Share Price	$0.014
Day High	$0.014
Day Low	$0.013
Last Close	$0.013
1AI Share Price Movement	$0.00 ( 3.85% )

Prices as at 13:15, 10 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Algorae Pharmaceuticals Limited (1AI) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Algorae Pharmaceuticals Limited (1AI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Algorae Pharmaceuticals Limited (1AI) price-sensitive announcements

1AI - Peter Mac Testing Validates AlgoraeOS v2

Algorae Pharmaceuticals Limited announced positive results from a preclinical validation s

Algorae Pharmaceuticals Limited (1AI)
3 Jul 2026 | 9:03 AM

1AI - Updated - NSW Health Public Hospital Supply Contract

Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical company, has been appointed

Algorae Pharmaceuticals Limited (1AI)
2 Jul 2026 | 9:47 AM

1AI - Algorae Awarded NSW Health Public Hospital Supply Contract

Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical company, announced that it h

Algorae Pharmaceuticals Limited (1AI)
1 Jul 2026 | 9:03 AM

1AI - Algorae Expands AI Drug Combination Pipeline

Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical company listed on the ASX as

Algorae Pharmaceuticals Limited (1AI)
18 May 2026 | 8:54 AM

Algorae Pharmaceuticals Limited (1AI) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID	Health Care	$27	Cleansing Notice	6 Jul 2026 4:29PM	$0.013	$0.014	risen by 3.85%
Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID	Health Care	$27	Application for quotation of securities - 1AI	6 Jul 2026 4:26PM	$0.013	$0.014	risen by 3.85%
Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID	Health Care	$27	Peter Mac Testing Validates AlgoraeOS v2	3 Jul 2026 9:03AM	$0.012	$0.014	risen by 12.50%
Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID	Health Care	$27	Updated - NSW Health Public Hospital Supply Contract	2 Jul 2026 9:47AM	$0.013	$0.014	risen by 3.85%
Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID	Health Care	$27	Algorae Awarded NSW Health Public Hospital Supply Contract	1 Jul 2026 9:03AM	$0.010	$0.014	risen by 35%
Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID	Health Care	$27	Company Secretary Appointment/Resignation	30 Jun 2026 4:19PM	$0.010	$0.014	risen by 35%

1AI Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$0.80	-$0.10	-61.50%	0.00%	0.0%
2024A	-$2.10	-$0.10	-18.80%	0.00%	0.0%
2023A	-$2.11	-$0.20	-27.30%	0.00%	0.0%

1AI Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Algorae Pharmaceuticals Limited (1AI)	$26M	-0.6154	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
CSL Limited (CSL)	$59,529M	0.1108	-0.1211	0.0167	13.3288	15.1646	14.9150	3.59%	2.93%	3.04%
Clinuvel Pharmaceuticals Limited (CUV)	$518M	0.0287	0.0000	0.0000	14.3175	0.0000	0.0000	0.49%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,615M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,627M	-1.3893	0.0000	-0.1287	0.0000	304.7794	349.7890	0.00%	0.00%	0.00%

1AI Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	10.00	0.00
Market	0.28	13.00	1.14	0.58
Sector	0.45	28.20	2.44	1.90

1AI Directors

Name	Position	Start Date
Mr David Richard Hainsworth	Executive Chairman, Executive Director, Interim CEO	30 Oct 2022
Mr Bradley John Dilkes	Non-Executive Director	30 Oct 2022
Mr David Gulland	Non-Executive Director	10 Mar 2026

Algorae Pharmaceuticals Limited (1AI) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
5 Mar 2026	HAINSWORTH, David	Buy	Indirect Shares	312,500	$0.012	$3,750.000
5 Mar 2026	HAINSWORTH, David	Exercise	Options	312,500	$0.012	$3,750.000
22 Dec 2025	HAINSWORTH, David	Issued	Options	5,125,000	$0.001	$5,125.000

See all changes in directors' interest & trades for Algorae Pharmaceuticals Limited (1AI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

1AI Management

Name	Position
Vishal Shah	Chief Commercial Officer
Catherine Earlie	Joint Company Secretary
Geraldine Holland	Joint Company Secretary

1AI Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Algorae Pharmaceuticals Limited (1AI). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
93,251,315 (5.53%)	Chunyan Niu

1AI Calendar of Events

Date	Event
26 February 2027	Report (Interim)
27 August 2026	Report (Annual)
27 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us